YM 16151-1

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341164

CAS#: 103434-30-6

Description: YM 16151-1 is a biochemical.


Chemical Structure

img
YM 16151-1
CAS# 103434-30-6

Theoretical Analysis

MedKoo Cat#: 341164
Name: YM 16151-1
CAS#: 103434-30-6
Chemical Formula: C30H37N3O9
Exact Mass: 583.253
Molecular Weight: 583.638
Elemental Analysis: C, 61.74; H, 6.39; N, 7.20; O, 24.67

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: YM 16151-1; YM-16151; YM16151.

IUPAC/Chemical Name: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2-(4-((2-hydroxy-3-phenoxypropyl)amino)butoxy)-5-nitrophenyl)-2,6-dimethyl-, dimethyl ester

InChi Key: GQJFGCIETONRNJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C30H37N3O9/c1-19-26(29(35)39-3)28(27(20(2)32-19)30(36)40-4)24-16-21(33(37)38)12-13-25(24)41-15-9-8-14-31-17-22(34)18-42-23-10-6-5-7-11-23/h5-7,10-13,16,22,28,31-32,34H,8-9,14-15,17-18H2,1-4H3

SMILES Code: CC1=C(C(C(=C(N1)C)C(=O)OC)c2cc(ccc2OCCCCNCC(COc3ccccc3)O)[N+](=O)[O-])C(=O)OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 583.638 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Uchida W, Shibasaki K, Matsuda Y, Asano M, Takenaka T. Cardiovascular effects of YM-16151-4: a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent in rats and dogs. J Cardiovasc Pharmacol. 1993 Aug;22(2):247-52. PubMed PMID: 7692165.

2: Uchida W, Shibasaki K, Asano M, Takenaka T. Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. PubMed PMID: 7685438.

3: Uchida W, Shibasaki K, Asano M, Takenaka T. Cardiovascular effects of YM-16151-1 and its optical isomers: a novel calcium entry blocking and beta 1-adrenoceptor blocking agent. Arch Int Pharmacodyn Ther. 1993 Jan-Feb;321:30-40. PubMed PMID: 8100704.

4: Uchida W, Shibasaki K, Asano M. Cardiovascular effects of a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent, YM-16151-4, in anesthetized and conscious dogs. J Cardiovasc Pharmacol. 1992 Jan;19(1):60-8. PubMed PMID: 1375689.

5: Drieu la Rochelle C, Berdeaux A, Richard V, Giudicelli JF. Coronary effects of a combined beta adrenoceptor blocking and calcium antagonist therapy in running dogs. J Cardiovasc Pharmacol. 1991 Dec;18(6):904-10. PubMed PMID: 1725905.

6: Shibasaki K, Uchida W, Matsuda Y, Asano M. Calcium entry blocking, beta 1-adrenoceptor blocking and hypotensive effects of YM-16151-4. Arch Int Pharmacodyn Ther. 1991 Sep-Oct;313:140-50. PubMed PMID: 1687772.

7: Asano M, Uchida W, Shibasaki K, Terai M, Inagaki O, Takenaka T, Matsumoto Y, Fujikura T. Pharmacological profiles of YM-16151-1 and its optical isomers: a novel calcium entry blocking and selective beta-1 adrenoceptor blocking agent. J Pharmacol Exp Ther. 1990 Jul;254(1):204-11. PubMed PMID: 1973196.